CD274 and non-small cell lung carcinoma: In the randomized phase 2 study CITYSCAPE, we evaluated the efficacy of first-line tiragolumab plus atezolizumab versus atezolizumab monotherapy in patients with PD-L1-positive (tumour proportion score (TPS) ≥ 1%) NSCLC.